IV Synercid

November 1999

Rhone-Poulenc Rorer is now marketing IV Synercid.

It's the new antibiotic of "last resort"...for vancomycin-resistant Enterococcus faecium (VREF).

Synercid is actually a combination of two antibiotics...quinupristin and dalfopristin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new approaches to controlling flu
Is it dangerous for DIASTOLIC blood pressure to drop too low when treating hypertension
dipyridamole (Persantine, etc) with aspirin to prevent stroke
foods that contain soy to reduce the risk of heart disease
Acne Zithromax (azithromycin) for acne
Osteoporosis Evista (raloxifene) is now approved to TREAT osteoporosis
Osteoporosis Actonel (risedronate) for osteoporosis
Infectious Diseases IV Synercid
Infectious Diseases treating depression caused by alpha-interferons
Depression DHEA may be useful for depression
Diabetes More diabetics on intensive therapy will use insulin pumps
Diabetes no longer be able to use BEEF insulin
Pediatrics famotidine (Pepcid) for autism
Breast Cancer Arimidex for breast cancer
Multiple Sclerosis Procarin, the experimental treatment for multiple sclerosis
estrogen cream (Premarin) for recurrent nosebleeds
taking their diarrhea vaccine, RotaShield, OFF the market
Practice withdrawing their quinolone antibiotic, Raxar (grepafloxacin)